Urolithin A trial finds no significant vascular benefit on primary endpoint

Urolithin A did not significantly improve the primary measure of blood-vessel function in a randomized trial published October 9 in JAMA Network Open. A secondary brain-response finding offers a reason for further investigation, but does not establish better cognition or protection against age-related disease.

The study enrolled 50 middle-aged adults with obesity. Brain blood-oxygen responses during a working-memory task increased relative to placebo, while performance on cognitive tasks did not significantly improve. The distinction matters for evaluating supplements studied for healthy aging: a physiological response and a benefit that people can experience are different outcomes.

### What the trial tested

The study’s previously published protocol describes a double-blind, placebo-controlled experiment involving adults aged 40 to 64 with a body mass index of at least 30. Participants were assigned to supplementation or placebo for four weeks, with assessments before and after treatment. The protocol appeared in Clinical Nutrition Open Science in 2025, ahead of this week’s results report.

The rationale centered on mitochondria, the cellular structures that produce energy. Urolithin A is a metabolite produced by gut microbes from certain plant compounds and has been investigated for its ability to stimulate mitophagy, the disposal of damaged mitochondria. The protocol proposed that targeting this process might help address obesity-associated dysfunction in the endothelium, the lining of blood vessels.

Researchers planned to examine both peripheral circulation and responses in the brain. That design separates several biological questions rather than treating vascular health as a single interchangeable measurement. Evidence concerning one part of the circulation cannot automatically answer questions about another.

### A secondary signal requires restraint

The primary endpoint was brachial artery flow-mediated dilation, a measure of how an arm artery widens following increased blood flow. The trial found no significant advantage over placebo. Other peripheral vascular measures also showed no significant treatment effect.

Forty-three participants completed the study; 74% of those enrolled were women. Its small size, four-week duration and single-site design limit the conclusions. The brain-response analysis used participants with complete measurements.

For interpretation, a negative primary endpoint deserves priority because it represents the central question chosen for the experiment. A secondary finding can help identify a more focused hypothesis for another trial, but cannot substitute for a demonstrated improvement in the original outcome. Equally, a nonsignificant result does not establish that every possible effect has been ruled out.

### How this fits the human evidence

An earlier randomized trial, published in January 2022, studied 66 adults aged 65 to 90 over four months. It found no significant benefit on its primary measures of six-minute walking distance and maximal energy production in hand muscle. Secondary tests showed better muscle endurance at two months; that between-group advantage was not significant at four months as the placebo group also improved.

That older experiment studied muscle outcomes in a different population. It therefore supplies context for the research program, rather than independent confirmation of the new brain finding. Together, the studies illustrate why claims about a compound should specify the population, measurement and follow-up period involved.

For healthspan research, the next question is whether a reproducible biological effect translates into sustained function or fewer clinical problems. Larger and longer trials would need to address that question directly. The current evidence does not support presenting urolithin A as an established way to prevent cognitive decline, cardiovascular events or disability.